ClearPoint Neuro Stock News

ClearPoint Neuro clears all debt from balance sheet after early repayment of principal & interest on $10 million convertible note held by PTC Therapeutics

ClearPoint's business is gaining momentum, with recent growth investments starting to pay off. Growth in system placements is an early indication of the potential boost that the OR system and laser therapy will provide. ClearPoint's biologics business also continues to progress. This was highlighted recently by uniQure's solid clinical trial data.

ClearPoint Neuro is an industry leader in providing tools for minimally invasive brain surgeries, neurosurgical laser therapy, and drug delivery to the brain. The company has established a deep moat by working with partners early in clinical work, making its products part of FDA submissions. Continuous growth is expected through partner programs, consulting fees, and possible royalties and mile...

ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Kyle Bauser - B. Riley Emily Christy - Stifel Operator Greetings, and welcome to the ClearPoint Neuro, Inc. Second Quarter 2024 Financial Results Conference Call.

Brain-computer interface (BCI) technology creates a direct link between the brain's electrical activity and a digital device. This connection can bring a vast range of benefits in assisting, augmenting and repairing human cognitive functions.

SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close.

Growth stocks have been on a wild ride for the past few years. The pandemic sent many soaring to unbelievable heights.

ClearPoint Neuro's business continues to perform well despite the stock struggling. The drug delivery business is thriving, which should be aided by maturing partner programs and the introduction of new services in coming years. The full market release of ClearPoint's operating room and laser solutions should help to revitalize the rest of the business.